Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Week's Exclusive Story
Up Over 200% in 2026, What's Next for AI Stock Aehr Test Systems?Authored by Leo Miller. First Published: 4/10/2026. 
Key Points
- AEHR has skyrocketed in 2026, being among the market's top performers.
- The company is generating orders and interest from many corners of the AI infrastructure market, exciting investors.
- The company's momentum in winning deals points to good things ahead, but AEHR's valuation remains a key risk.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Aehr Test Systems (NASDAQ: AEHR), a small company in the semiconductor industry, has been indisputably one of the market’s best performers of 2026. This year, AEHR is one of just five stocks in the Russell 3000 Index to deliver a return of more than 200%. Putting the Russell 3000 in context highlights how notable that is. The index tracks the 3,000 largest U.S. stocks, covering roughly 98% of the investable U.S. equity market. That breadth makes AEHR’s performance a standout among a vast universe of companies. The company, which makes equipment to stress-test semiconductors, has announced multiple deals this year. Despite mixed quarterly results, the stock surged nearly 26% after the latest report. Below, we look at what’s driven Aehr’s gains and what investors should weigh going forward. Silicon Photonics Deal Boosts AEHR Stock
There's a company sitting on a deposit independently valued at $2.8 billion - currently trading at a market cap of roughly $700 million. That's a 4-to-1 disconnect.
The Pentagon has already invested. Lockheed's Skunk Works signed a research partnership, and the EXIM Bank is processing up to $800 million in financing. A federal deadline of July 13, 2026 is forcing the issue.
The stock is still trading under $6. Check the valuation math and get the ticker now
Most of Aehr’s 2026 gains occurred in less than two weeks. The stock began the year near $20 and traded around $30 by late March; soon afterward it more than doubled, topping $65. March 31 was a major catalyst: shares jumped more than 23% after the company announced a key customer win. Aehr said it had secured a new silicon photonics customer ordering multiple FOX-XP systems. Aehr described the customer as “a global leader in networking products and solutions and a major supplier to the data center optical transceiver market.” Optical transceivers are being rapidly adopted in AI data centers because they enable high-bandwidth interconnects needed to move massive amounts of data. Suppliers such as Coherent (NYSE: COHR) and Lumentum (NASDAQ: LITE) have seen strong share-price gains as demand for optical components has risen. For Aehr, entering this market is a strategic win — and the company says follow-on orders are possible in 2026. Importantly, the customer is buying systems for both engineering qualification and high-volume production. Customers typically qualify systems before ramping production; doing both simultaneously signals confidence in Aehr’s technology and urgency in the customer’s deployment plans, increasing the likelihood of further orders. Aehr Looks Poised to See Significant Growth in Fiscal 2027In its latest quarter, Aehr reported revenue of $10.3 million, below analysts' estimate of $10.85 million. Its loss of $0.05 per share was narrower than the $0.07 that had been expected. The company reiterated guidance for $25 million to $30 million in revenue for the second half of fiscal 2026 (FY2026) and maintained an adjusted loss-per-share outlook of $0.09 to $0.05. Note that Aehr recently reported Q3 FY2026 results; its fiscal calendar is offset from the calendar year. More compelling is the company’s bookings activity. Aehr recorded bookings of $37.2 million in the quarter — more than 3.5 times its revenue — which points to materially larger revenue ahead. Management now expects second-half FY2026 bookings to come in at the high end of its $60 million to $80 million range. The company’s effective backlog also reached a record $50.9 million, slightly above the high end of its FY2026 revenue guidance. That backlog provides meaningful support for higher sales into FY2027. AEHR Continues to Show It Is Not a Name to IgnoreOverall, Aehr continues to demonstrate an ability to win customers and orders. It has relationships with an AI-processor developer and silicon-photonics firms — two areas with growing demand. The company is also in discussions with another AI processor supplier, multiple high-bandwidth memory companies, and a NAND flash supplier. These memory technologies are among the fastest-growing segments in AI infrastructure. Valuation is a concern: AEHR’s market capitalization exceeds $2 billion, yet the company expects up to roughly $50 million in revenue for FY2026. That makes it hard to call the stock undervalued today. Still, the growth runway in AI-related markets is significant, and Aehr’s recent wins suggest there could be upside if more customers follow through. Notably, analysts at Craig Hallum upgraded AEHR from a Hold to a Buy after the earnings report and set a $68 price target — a level the shares briefly exceeded soon after the upgrade. |
Post a Comment
Post a Comment